$ 1.71
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is 'expensive' on EV/EBITDA, tra
Target Price
The average target price of EQ is 2.4 and suggests 47% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
